Article

Gut Pathogens: enteric health at the interface of changing microbiology

Pathogen Biology Laboratory, Department of Biotechnology, University of Hyderabad, Hyderabad, India. .
Gut Pathogens (Impact Factor: 2.07). 02/2009; 1(1):1. DOI: 10.1186/1757-4749-1-1
Source: PubMed

ABSTRACT The International Society for Genomic and Evolutionary Microbiology (ISOGEM) in collaboration with BioMed Central Ltd. has launched Gut Pathogens with the aim of providing a high-quality forum for research on enteric infections of humans and animals. The journal led by three Editors-in-Chief and supported by a highly qualified and organized international Editorial Board publishes open access research articles of repute in areas of biology and the pathogenesis of bacterial, parasitic and viral infections of the gut including their diagnosis, epidemiology and clinical management.

Download full-text

Full-text

Available from: Leonardo A Sechi, Aug 01, 2015
0 Followers
 · 
124 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As the National Institutes of Health-funded Human Microbiome Project enters its second phase, and as a major part of this project focuses on the human gut microbiome and its effects on human health, it might help us to travel a century back in time and examine how microbiologists dealt with microbiome-related challenges similar to those of the 21st century using the tools of their time. An article by Arthur I. Kendall, published in The Journal of Biological Chemistry in November 1909 (Some observations on the study of the intestinal bacteria J Biol Chem 1909, 6:499-507), offers a visionary insight into many of today's hot research questions.
    Gut Pathogens 12/2009; 1(1):21. DOI:10.1186/1757-4749-1-21 · 2.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present investigation was to determine whether the bacterium Dietzia subsp. C79793-74, previously shown to inhibit growth of Mycobacterium subsp. paratuberculosis under in vitro culture conditions, has therapeutic value as a probiotic for adult cattle with paratuberculosis. Animals were obtained from several herds with evidence of disease based on seropositivity and/or fecal shedding. Sixty-eight cows with initial evidence of Stage II or III paratuberculosis and 2 with an initial Stage IV disease were evaluated longitudinally. Animals were either treated daily with variable, disease-dependent doses of Dietzia (n = 48) or left untreated (n = 22). Clinical aspects of disease (diarrhea, emaciated, cachectic and appetite) were recorded until the animal recovered or required euthanasia due to advanced clinical paratuberculosis or other severe conditions. Paratuberculosis parameters-antibody serology (ELISA, AGID) and fecal culture-were longitudinally monitored over the lifetime of each animal. The results indicated that daily treatment with Dietzia was therapeutic for paratuberculosis cows based on: (a) longitudinal decline in ELISA values only occurred in animals that were treated; (b) prolonged survival was dependant upon treatment--the length being directly associated with low initial ELISA values; and (c) treated animals were the only ones cured of disease. Further investigations are envisaged to determine optimal, long-term dosages that may result in even better therapeutic outcomes as well as to evaluate potential application for therapy of the Johne's disease, human-counterpart, Crohn's disease.
    Virulence 05/2010; 1(3):145-55. DOI:10.4161/viru.1.3.10897 · 3.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The gut microbiota plays a crucial role in maintaining health. Alterations of the gut bacterial population have been associated with a number of diseases. Past and recent studies suggest that one can positively modify the contents of the gut microbiota by introducing prebiotics, probiotics, synbiotics, and other therapeutics. This paper focuses on probiotic modulation of the gut microbiota by their delivery to the lower gastrointestinal tract (GIT). There are numerous obstacles to overcome before microorganisms can be utilized as therapeutics. One important limitation is the delivery of viable cells to the lower GIT without a significant loss of cell viability and metabolic features through the harsh conditions of the upper GIT. Microencapsulation has been shown to overcome this, with various types of microcapsules available for resolving this limitation. This paper discusses the gut microbiota and its role in disease, with a focus on microencapsulated probiotics and their potentials and limitations.
    BioMed Research International 07/2011; 2011(1110-7243):981214. DOI:10.1155/2011/981214 · 2.71 Impact Factor
Show more